Last reviewed · How we verify
JNJ-56021927 Softgel Capsule
At a glance
| Generic name | JNJ-56021927 Softgel Capsule |
|---|---|
| Also known as | ARN-509 |
| Sponsor | Aragon Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants (PHASE1)
- A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-56021927 Softgel Capsule CI brief — competitive landscape report
- JNJ-56021927 Softgel Capsule updates RSS · CI watch RSS
- Aragon Pharmaceuticals, Inc. portfolio CI